Alkermes plc (ALKS)
NASDAQ: ALKS · Real-Time Price · USD
35.32
-0.18 (-0.51%)
Feb 21, 2025, 4:00 PM EST - Market closed
Alkermes Revenue
In the year 2024, Alkermes had annual revenue of $1.56B, down -6.36%. Alkermes had revenue of $429.99M in the quarter ending December 31, 2024, with 13.91% growth.
Revenue (ttm)
$1.56B
Revenue Growth
-6.36%
P/S Ratio
3.75
Revenue / Employee
$865,351
Employees
1,800
Market Cap
5.74B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.56B | -105.77M | -6.36% |
Dec 31, 2023 | 1.66B | 551.61M | 49.61% |
Dec 31, 2022 | 1.11B | -61.96M | -5.28% |
Dec 31, 2021 | 1.17B | 134.99M | 13.00% |
Dec 31, 2020 | 1.04B | -132.19M | -11.29% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ALKS News
- 9 days ago - Alkermes plc (ALKS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025 - PRNewsWire
- 16 days ago - Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025 - PRNewsWire
- 7 weeks ago - Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 3 months ago - Alkermes to Participate in Upcoming Investor Conferences - PRNewsWire
- 3 months ago - Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth - Seeking Alpha
- 3 months ago - Alkermes to Participate in Two Upcoming Investor Conferences - PRNewsWire
- 3 months ago - Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences - PRNewsWire